Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
THEOPHYL-SR vs AEROLATE III
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Theophylline is a methylxanthine that inhibits phosphodiesterase, increasing cyclic AMP levels, and antagonizes adenosine receptors, leading to bronchodilation and anti-inflammatory effects.
AEROLATE III (theophylline) is a bronchodilator that inhibits phosphodiesterase, increasing intracellular c AMP levels, leading to relaxation of bronchial smooth muscle and suppression of airway inflammation.
Treatment of asthma,Treatment of chronic obstructive pulmonary disease (COPD)
Treatment and prophylaxis of bronchospasm associated with asthma, chronic bronchitis, and emphysema,Off-label: Apnea of prematurity (oral/IV theophylline)
300 mg orally every 12 hours, with dosing titrated to achieve serum trough concentrations of 5-15 mcg/m L.
Inhalation: 2 inhalations (200 mcg) twice daily, max 4 inhalations (400 mcg) per day. Oral: 4 mg twice daily, max 8 mg per day.
Adults: 8-10 hours (range 3-12); Neonates: 20-30 hours; Smokers: 4-5 hours; Cirrhosis: 30-40 hours. Dose adjustments needed based on half-life variations.
Terminal half-life 12-15 hours; clinically allows twice-daily dosing
Hepatic via CYP1A2, CYP2E1, and CYP3A4; demethylation and oxidation to inactive metabolites (1-methyluric acid, 3-methylxanthine, 1,3-dimethyluric acid).
Primarily hepatic via cytochrome P450 1A2 (CYP1A2); also CYP2E1 and CYP3A4; exhibits nonlinear pharmacokinetics.
Renal: ~10% unchanged; Hepatic metabolism (90%) via CYP1A2, 3A4; metabolites (caffeine, 3-methylxanthine) excreted renally. Total clearance predominantly hepatic.
Renal: 60% unchanged; biliary/fecal: 30% as metabolites; 10% other
40-60% primarily to albumin.
92-96%, primarily to albumin and alpha-1-acid glycoprotein
0.3-0.5 L/kg (1.0-1.5 L/kg in neonates). Reflects distribution into total body water; higher in dehydrated states.
Vd 1.5-2.0 L/kg, indicating extensive tissue distribution
Oral immediate-release: 96-100%; Sustained-release: 90-100% (variable among formulations).
Oral: 40-50%; Inhalation: 20-30%
No specific GFR-based adjustment required, but serum concentrations should be monitored due to altered clearance. For GFR <10 m L/min, reduce dose by 50% and monitor levels.
No adjustment needed for GFR >30 m L/min. For GFR 10-30 m L/min: use 50% of usual dose. For GFR <10 m L/min: avoid use.
Child-Pugh Class A: reduce dose by 50%; Child-Pugh Class B: reduce dose by 60%; Child-Pugh Class C: reduce dose by 80% and monitor serum concentrations closely.
Child-Pugh A: no adjustment. Child-Pugh B: reduce dose by 50%. Child-Pugh C: avoid use.
Initial dose: 5 mg/kg/day orally in 2 divided doses, increasing by 2 mg/kg/day every 3 days to maximum 20 mg/kg/day, with monitoring of serum concentrations.
Children 2-11 years: 1 inhalation (100 mcg) twice daily via metered-dose inhaler. Children 12 years and older: same as adult.
Start at lower end of dosing range (e.g., 200 mg every 12 hours) and titrate slowly due to reduced hepatic clearance; monitor serum concentrations and adjust to therapeutic trough of 5-15 mcg/m L.
No specific dose adjustment but monitor for increased systemic effects; start at lowest effective dose.
No FDA black box warning.
No FDA black box warning.
Use with caution in patients with cardiac disease (e.g., arrhythmias), seizure disorders, peptic ulcer disease, hepatic impairment, and in elderly patients. Monitor serum theophylline levels to avoid toxicity.
Monitor serum theophylline concentrations due to narrow therapeutic index; risk of toxicity at levels >20 mcg/m L; use caution in patients with cardiac disease, hepatic impairment, or seizures; may exacerbate arrhythmias; drug interactions with cimetidine, fluoroquinolones, macrolides, allopurinol, oral contraceptives, smoking, and others.
Hypersensitivity to theophylline or any component of the formulation; active peptic ulcer disease; seizure disorder (unless appropriately controlled with anticonvulsants).
Hypersensitivity to theophylline or any component; pre-existing cardiac arrhythmias (e.g., ventricular tachycardia); recent myocardial infarction; uncontrolled seizure disorders.
Avoid large amounts of caffeine-containing foods/beverages (coffee, tea, cola, chocolate) as they may increase adverse effects. Charcoal-broiled foods can increase clearance, potentially decreasing effectiveness. High-carbohydrate/low-protein diets may increase theophylline levels. St. John's wort may decrease theophylline levels.
Avoid significant intake of caffeine-containing foods/beverages (coffee, tea, cola, chocolate) as they may increase CNS stimulation and risk of toxicity. Charcoal-broiled foods and a high-protein diet may increase clearance. Maintain consistent dietary patterns; avoid extremes of protein/carbohydrate intake.
FDA Pregnancy Category C. First trimester: No increased risk of major malformations reported in humans; animal studies show fetal harm at high doses. Second trimester: Potential for maternal tachycardia and uterine relaxation, not teratogenic. Third trimester: Risk of neonatal apnea, bradycardia, and jitteriness at birth if maternal levels are supratherapeutic; no structural anomalies.
AEROLATE III (theophylline) is FDA Pregnancy Category C. First trimester: No well-controlled studies; potential risk cannot be ruled out. Second/third trimesters: Increased fetal heart rate, jitteriness, and risk of neonatal apnea with high maternal serum concentrations (>15 mcg/m L). Avoid near term due to prolonged neonatal half-life.
Excreted into breast milk; M/P ratio approximately 0.6-0.7. Infant dose ~1-10% of maternal weight-adjusted dose; monitor infant for irritability or insomnia. AAP considers compatible with breastfeeding with caution.
Theophylline is excreted into breast milk with an M/P ratio of approximately 0.7. Infant serum levels can reach 50% of maternal levels; risk of irritability and sleep disturbances in nursing infants. Use with caution and monitor infant for signs of toxicity.
Increased clearance and volume of distribution in pregnancy; dose may need to be increased by 20-30% in second and third trimesters. Monitor levels and adjust based on clinical response and trough concentrations.
Pregnancy may increase theophylline clearance due to enhanced hepatic metabolism and increased renal blood flow. Dose adjustments are often required: monitor serum levels regularly and adjust dose to maintain therapeutic levels. Typically, dose may need to be increased by 20-50% in second and third trimesters.
Theophylline has a narrow therapeutic index (10-20 mcg/m L). Monitor levels due to significant interindividual pharmacokinetic variability. Smoking induces metabolism; dose adjustments needed when starting/stopping smoking. Avoid in tachyarrhythmias, seizure disorders, or peptic ulcer disease. Cimetidine, ciprofloxacin, and erythromycin increase theophylline levels. Convert between immediate-release and sustained-release formulations cautiously. Use with caution in heart failure, liver disease, and elderly patients due to reduced clearance.
AEROLATE III (theophylline) is a bronchodilator with a narrow therapeutic index; monitor serum levels (target 10-20 mcg/m L). Caffeine and smoking increase clearance; hepatic impairment, heart failure, and certain drugs (e.g., cimetidine, fluoroquinolones) decrease clearance. Avoid use in patients with active peptic ulcer or seizure disorders. Titrate dose slowly to minimize nausea, vomiting, and arrhythmias.
Take exactly as prescribed; do not crush or chew sustained-release tablets.,Do not change brands or formulations without consulting your doctor.,Avoid large amounts of caffeine (coffee, tea, cola) as it may increase side effects.,Report symptoms of toxicity: persistent nausea/vomiting, insomnia, tremors, seizures, or rapid/irregular heartbeat.,If you smoke, inform your doctor, as dose adjustments may be needed.,Keep all appointments for blood level monitoring.,Do not stop abruptly; may cause rebound bronchospasm.
Take this medication exactly as prescribed; do not crush or chew extended-release tablets.,Avoid consuming large amounts of caffeine (coffee, tea, chocolate) as it may increase side effects like jitteriness and insomnia.,Inform your doctor if you experience nausea, vomiting, rapid heartbeat, or seizures.,Do not stop taking this medication abruptly; taper under medical supervision.,Keep all appointments for blood tests to monitor theophylline levels.,Avoid smoking or using nicotine products, as they affect how the medication works.,Carry a list of all medications you take, as many can interact with theophylline.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about THEOPHYL-SR vs AEROLATE III, answered by our medical review team.
THEOPHYL-SR is a Bronchodilator that works by Theophylline is a methylxanthine that inhibits phosphodiesterase, increasing cyclic AMP levels, and antagonizes adenosine receptors, leading to bronchodilation and anti-inflammatory effects.. AEROLATE III is a Bronchodilator that works by AEROLATE III (theophylline) is a bronchodilator that inhibits phosphodiesterase, increasing intracellular c AMP levels, leading to relaxation of bronchial smooth muscle and suppression of airway inflammation.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between THEOPHYL-SR and AEROLATE III depend on the specific clinical indication. These are both Bronchodilator agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of THEOPHYL-SR is: 300 mg orally every 12 hours, with dosing titrated to achieve serum trough concentrations of 5-15 mcg/m L.. The standard adult dose of AEROLATE III is: Inhalation: 2 inhalations (200 mcg) twice daily, max 4 inhalations (400 mcg) per day. Oral: 4 mg twice daily, max 8 mg per day.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between THEOPHYL-SR and AEROLATE III in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. THEOPHYL-SR is classified as Category C. FDA Pregnancy Category C. First trimester: No increased risk of major malformations reported in humans; animal studies show fetal harm at high doses. Second trimester: Potential fo. AEROLATE III is classified as Category C. AEROLATE III (theophylline) is FDA Pregnancy Category C. First trimester: No well-controlled studies; potential risk cannot be ruled out. Second/third trimesters: Increased fetal h. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.